Up next

Supplier News: Siegfried, Vetter, Made Scientific & More 

The latest from CDMOs, CMOs, and suppliers featuring Siegfried, Vetter, Made Scientific, OrganaBio, Thermo Fisher Scientific, Piramal Pharma Solutions, Hovione, Andelyn Biosciences and Avid Bioservices.  

Chemicals/Chemical API Manufacturing 
* Siegfried Completes Acquisition of Noramco, Extractas Biosciences 
* Piramal Pharma Solutions Opens ADC Suite 
Biologics Manufacturing 
* Made Scientific, Roosterbio Partner for Stem-Cell Mfg
* Organabio Acquires Excellos  
* Thermo Fisher Launches Cell-Therapy Mfg Platform  
* Andelyn Biosciences Launches Lentiviral Vector Mfg Platform 
Formulation Development/Drug Product Manufacturing 
* Vetter Breaks Ground on New Injectable Mfg Facility 
* Hovione Announces Leadership Transition, Interim Co-CEOs  
Appointments 
* Avid Bioservices Names New Chief Commercial Officer 

Chemicals/Chemical API Manufacturing 

Siegfried Completes Acquisition of Noramco, Extractas Biosciences 
Siegfried, a CDMO of drug substances and drug products, has completed its previously announced acquisition of three drug-substances sites of Noramco, Extractas Biosciences, and Purisys (a Noramco subsidiary) from affiliates of the private-equity firm, SK Capital Partner. 

The acquired businesses include three small-molecule drug-substances sites with approximately 400 employees. The acquisitions included: (1) Noramco’s commercial-scale manufacturing site in Wilmington, Delaware; (2) Purisys’ clinical active pharmaceutical ingredient (API) development and manufacturing facility in Athens, Georgia; and (3) Extractas Bioscience, a manufacturer of purified products based in Westbury, Tasmania, Australia. 

Following the closing, SK Capital retains ownership of Halo Pharmaceuticals, a CDMO of drug products purchased by Noramco in 2023. Going forward, Lee Karras and Alan Majewski, CEO and CFO, respectively, of the Noramco Group, will remain with Halo Pharmaceuticals and continue to lead the business in their current roles. 

Source: SK Capital 

Piramal Pharma Solutions Opens ADC Suite 
Piramal Pharma Solutions, a CDMO of active pharmaceutical ingredients and drug products, has opened a new payload-linker development and manufacturing suite at its Riverview, Michigan drug-substance facility.  

The launch is a key element of the company’s broader $90-million investment plan to extend US-based manufacturing capabilities, announced in 2025. In addition to the payload-linker suite, the plan will add new technology and enhanced commercial-scale manufacturing capabilities at the company’s dedicated sterile injectables facility in Lexington, Kentucky. 

Source: Piramal Pharma Solutions 

Biologics Manufacturing 

Made Scientific, Roosterbio Partner for Stem-Cell Mfg 
Made Scientific, a Princeton, New Jersey-based cell-therapy CDMO, and RoosterBio, a supplier of human mesenchymal stem cells (MSCs), engineered bioprocess media, and bioprocess development services, have announced a strategic partnership integrating RoosterBio’s MSC and extracellular vesicle (EV) manufacturing platforms into Made Scientific’s CDMO service offering, which spans from initial process development through commercial-scale GMP manufacturing. Under the agreement, Made Scientific will incorporate RoosterBio’s off-the-shelf MSCs, proprietary MSC expansion and EV collection media across its GMP operations. 

Source: Made Scientific 

Organabio Acquires Excellos 
OrganaBio, a manufacturer of GMP cells and blood products and provider of cell isolation and cryopreservation services, has acquired substantially all of the operating assets of San Diego-based Excellos to create a cell-therapy CDMO. Newly formed OrganaBio subsidiary Excellos Labs will be responsible for San Diego operations going forward. 

The company’s combined platform consists of multiple facilities across the US. OrganaBio’s Miami headquarters anchors the East Coast with adult leukapheresis (via its HemaCenter subsidiary), birth tissue and cord blood sourcing (via its GaiaGift subsidiary), ISO 7 cGMP cleanrooms, process development, QC/analytical testing, PBMC isolation, and cryopreservation. On the West Coast, OrganaBio operates cell-processing and cryopreservation labs in San Francisco and Irvine, California, and now adds Excellos’ downtown San Diego facility, with five ISO 7 cGMP cleanroom suites supporting autologous and allogeneic cell-therapy manufacturing, cell isolation and enrichment, expansion, and fill-finish. 

Source: OrganaBio 

Thermo Fisher Launches Cell-Therapy Mfg Platform 
Thermo Fisher Scientific has launched its new Gibco CTS DynaXS single-use bioreactor, an expansion platform designed to help cell-therapy developers scale manufacturing. 

Source: Thermo Fisher Scientific 

Andelyn Biosciences Launches Lentiviral Vector Mfg Platform 
Andelyn Biosciences, a CDMO of cell and gene therapies, has announced the launch of its LVV curator platform, a standardized lentiviral vector (LVV) manufacturing solution built on the same modular approach that supports clinical and commercial adeno-associated virus (AAV) programs. 

Source: Andelyn Biosciences 

Formulation Development/Drug Product Manufacturing 

Vetter Breaks Ground on New Injectable Mfg Facility 
Vetter, a CDMO of drug product development, clinical, and commercial aseptic filling and packaging, has started construction on its new site in Saarlouis, Germany.  

During the first construction phase, the company will build a facility for the commercial production of injectable drugs on the 95-acre industrial site. In total, Vetter will invest almost half a billion euros in the site by the planned commissioning in 2031. Once operational, the facility will create 400 to 500 new jobs. In the first expansion phase, Vetter will build a 50,000-square-meter manufacturing site, along with production-related facilities including laboratories and warehouses. Initially, three cleanrooms are planned for the aseptic production of innovative and complex drug products: two for filling pre-sterilized syringes and one for filling vials. 

Source: Vetter 

Hovione Announces Leadership Transition, Interim Co-CEOs 
Hovione, a CDMO of drug substances and drug products, reports that Jean Luc Herbeaux, the company’s Chief Executive Officer (CEO), will be stepping down from his role as CEO for personal reasons, effective May 21, 2026. He will continue with the company until September 30, 2026, to facilitate a smooth transition

The company’s Board has initiated a succession process to appoint the company´s new CEO. In the interim, the Board has appointed António Almeida, currently Chief Financial Officer, and Dr. Marco Gil, currently Senior Vice President, Sales & Marketing) as co-Chief Executive Officers, effective May 21, 2026.

Separately, Hovione and Industrial Design Consultancy (IDC), a global product development company, have announced that their intranasal drug delivery platform has reached a new milestone, with its lead single-use nasal dry-powder device available for commercial partnerships. The companies have completed the device design and established initial device manufacturing and supply capability, 

Source: Hovione and Hovione (CEO)

Appointments 

Avid Bioservices Names New Chief Commercial Officer 
Avid Bioservices, a biologics CDMO, has announced the appointment of Kerri McCullough Wood, formerly Chief Commercial Officer at TAPI, a division of Teva, as Chief Commercial Officer. She is a seasoned biopharma executive with nearly three decades of experience across API, CDMO, and drug-product services. She joins Avid following her role as Chief Commercial Officer at TAPI, where she led a global organization spanning 15 countries and was responsible for executing commercial strategy, accelerating growth initiatives, building strong partnerships with global pharmaceutical companies, and enhancing organizational performance across the business. 

Source: Avid Bioservices